To this end, we investigated methylation of the MGMT promoter by MSP, PSQ and MS-MLPA in 35 FFPE glioblastoma tissues derived from patients treated with dose-intensified TMZ in a prospective clinical phase II trial (UKT-05) [5]. The gene discussed is MGMT; the disease is glioblastoma.